Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC is a phase 3, interventional study registered as NCT06031558 by Shouyao Holdings (Beijing) Co. LTD, with a registry enrolment figure of 120 participants, started 2023-10-31 and due to reach its primary completion in 2025-04-10. Interventions recorded: SY-5007. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Assessment of ORR by independent review committee (IRC).. Lung eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of locally advanced (with a tumor lesion that cannot be eradicated by surgery or radiotherapy as assessed by the investigators) or metastatic NSCLC". Sites: China. No results are recorded here; the registry entry is the source.